We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 18, 2019

6 vs 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
6 Versus 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer (PERSEPHONE): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial
Lancet 2019 Jun 06;[EPub Ahead of Print], HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, AN Harnett, ML Ah-See, R Simcock, D Rea, S Raj, P Woodings, M Harries, D Howe, K Raynes, HB Higgins, M Wilcox, C Plummer, J Mansi, I Gounaris, B Mahler-Araujo, E Provenzano, A Chhabra, JE Abraham, C Caldas, PS Hall, C McCabe, C Hulme, D Miles, AM Wardley, DA Cameron, JA Dunn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading